Physician profile
Neeru Kumar
NPI 1255650685
$21,075.63
in general payments reported to CMS, 2019-2025
18 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $12.97 · 2021: $1,025 · 2022: $2,322 · 2023: $10K · 2024: $6,842 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $4,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,050.00 |
| Food and Beverage | $4,315.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $19,319.62 | 2021-2025 | Farxiga, Lokelma, Saphnelo |
| Horizon Therapeutics Plc | $788.56 | 2019-2023 | Krystexxa, Uplizna |
| Amgen INC. | $150.01 | 2023-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $127.34 | 2022-2023 | |
| Abbvie INC. | $125.00 | 2023 | |
| Travere Therapeutics, INC. | $124.77 | 2025 | Filspari |
| Celgene Corporation | $124.77 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.52 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $43.34 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $36.90 | 2019 | |
| Fresenius USA Marketing, INC. | $35.47 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $24.18 | 2022 | |
| Abbott Laboratories | $22.48 | 2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $22.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.58 | 2023 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.54 | 2025 | |
| Allergan, INC. | $17.96 | 2019 | |
| Vifor Pharma, INC. | $17.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeru Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.